158 related articles for article (PubMed ID: 29957351)
1. Progressive visual function impairment as the predominant symptom of the transition phase to secondary progressive multiple sclerosis: A case report.
Giordano A; Colombo B; Spinelli EG; Gelibter S; Guerrieri S; Leocani L; Comi G; Martinelli V
Mult Scler Relat Disord; 2018 Aug; 24():69-71. PubMed ID: 29957351
[TBL] [Abstract][Full Text] [Related]
2. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
3. Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis.
Maier S; Barcutean L; Andone S; Manu D; Sarmasan E; Bajko Z; Balasa R
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901807
[TBL] [Abstract][Full Text] [Related]
4. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
[TBL] [Abstract][Full Text] [Related]
5. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
Antel J; Antel S; Caramanos Z; Arnold DL; Kuhlmann T
Acta Neuropathol; 2012 May; 123(5):627-38. PubMed ID: 22327362
[TBL] [Abstract][Full Text] [Related]
6. [Controversies in neurology: Diagnosis, follow up and therapy of multiple sclerosis with pathomechanismal approach].
Vécsei L
Ideggyogy Sz; 2021 Jul; 74(7-08):249-255. PubMed ID: 34370413
[TBL] [Abstract][Full Text] [Related]
7. The transition from relapsing-remitting MS to irreversible disability: clinical evaluation.
Trojano M; Paolicelli D; Bellacosa A; Cataldo S
Neurol Sci; 2003 Dec; 24 Suppl 5():S268-70. PubMed ID: 14652786
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis.
Katz Sand I; Krieger S; Farrell C; Miller AE
Mult Scler; 2014 Oct; 20(12):1654-7. PubMed ID: 24493475
[TBL] [Abstract][Full Text] [Related]
9. Clinical and laboratory characteristics of secondary progressive MS.
Palace J
J Neurol Sci; 2003 Feb; 206(2):131-4. PubMed ID: 12559499
[TBL] [Abstract][Full Text] [Related]
10. Walking capacity and ability are more impaired in progressive compared to relapsing type of multiple sclerosis.
Feys P; Bibby BM; Baert I; Dalgas U
Eur J Phys Rehabil Med; 2015 Apr; 51(2):207-10. PubMed ID: 25180640
[TBL] [Abstract][Full Text] [Related]
11. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.
Pulizzi A; Rovaris M; Judica E; Sormani MP; Martinelli V; Comi G; Filippi M
Arch Neurol; 2007 Aug; 64(8):1163-8. PubMed ID: 17698707
[TBL] [Abstract][Full Text] [Related]
12. [New therapeutic approaches in progressive multiple sclerosis].
Faissner S; Gold R
Fortschr Neurol Psychiatr; 2019 Nov; 87(11):653-671. PubMed ID: 31783427
[TBL] [Abstract][Full Text] [Related]
13. Comparison of multifocal visual evoked potential, standard automated perimetry and optical coherence tomography in assessing visual pathway in multiple sclerosis patients.
Laron M; Cheng H; Zhang B; Schiffman JS; Tang RA; Frishman LJ
Mult Scler; 2010 Apr; 16(4):412-26. PubMed ID: 20207786
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis.
Choi IY; Lee P; Hughes AJ; Denney DR; Lynch SG
Mult Scler; 2017 Jun; 23(7):956-962. PubMed ID: 27620894
[TBL] [Abstract][Full Text] [Related]
15. Cortical sources of resting state electroencephalographic rhythms differ in relapsing-remitting and secondary progressive multiple sclerosis.
Babiloni C; Del Percio C; Capotosto P; Noce G; Infarinato F; Muratori C; Marcotulli C; Bellagamba G; Righi E; Soricelli A; Onorati P; Lupattelli T
Clin Neurophysiol; 2016 Jan; 127(1):581-590. PubMed ID: 26111485
[TBL] [Abstract][Full Text] [Related]
16. Functional connectivity changes within specific networks parallel the clinical evolution of multiple sclerosis.
Basile B; Castelli M; Monteleone F; Nocentini U; Caltagirone C; Centonze D; Cercignani M; Bozzali M
Mult Scler; 2014 Jul; 20(8):1050-7. PubMed ID: 24326671
[TBL] [Abstract][Full Text] [Related]
17. Clinical-MRI correlations in the secondary progressive phase of MS: lessons from the treatment trials.
Clanet M; Cassol E; Manelfe C; Berry I
J Neurol Sci; 2003 Feb; 206(2):139-44. PubMed ID: 12559501
[TBL] [Abstract][Full Text] [Related]
18. Secondary progressive multiple sclerosis - clinical course and potential predictive factors.
Pokryszko-Dragan A; Gruszka E; Bilińska M; Dubik-Jezierzańska M
Neurol Neurochir Pol; 2008; 42(1):6-11. PubMed ID: 18365957
[TBL] [Abstract][Full Text] [Related]
19. Diagnosing 'transition' to secondary progressive multiple sclerosis (SPMS): A step-by-step approach for clinicians.
Hamdy E; Talaat F; Ramadan I; Marouf H; Hamdy MM; Sadallah H; El-Ashmawy GAH; Elsalamawy D; Said SM
Mult Scler Relat Disord; 2022 Apr; 60():103718. PubMed ID: 35279626
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and management of primary progressive multiple sclerosis.
Jenkins TM; Khaleeli Z; Thompson AJ
Minerva Med; 2008 Apr; 99(2):141-55. PubMed ID: 18431323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
